Financials data is unavailable for this security.
View more
Year on year Beijing Tiantan Biological Products Corp Ltd grew revenues 21.57% from 4.26bn to 5.18bn while net income improved 25.99% from 880.92m to 1.11bn.
| Gross margin | 54.23% |
|---|---|
| Net profit margin | 33.05% |
| Operating margin | 39.94% |
| Return on assets | 11.47% |
|---|---|
| Return on equity | 12.59% |
| Return on investment | 16.75% |
More ▼
Cash flow in CNYView more
In 2023, Beijing Tiantan Biological Products Corp Ltd increased its cash reserves by 29.11%, or 638.58m. The company earned 2.39bn from its operations for a Cash Flow Margin of 46.20%. In addition the company used 1.25bn on investing activities and also paid 508.08m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.38 |
|---|---|
| Tangible book value per share | 4.72 |
More ▼
Balance sheet in CNYView more
| Current ratio | 5.51 |
|---|---|
| Quick ratio | 3.31 |
| Total debt/total equity | 0.006 |
|---|---|
| Total debt/total capital | 0.0046 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 199.98% and 25.99%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.31% |
|---|---|
| Div growth rate (5 year) | 38.97% |
| Payout ratio (TTM) | 19.40% |
| EPS growth(5 years) | 14.76 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.15 |
More ▼
